OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Home » Week of 4/22/24-4/26/24
The Viridian Value Tracker is the most comprehensive valuation product in the industry.
Interestingly, the psychedelics sector had lower market-to-book ratios across all quartiles on 5/1/24 compared to 4/19/24. On an EV/revenue basis, the five companies with 2024 revenue estimates had a median EV/ 2024 revenue of 4.45x, unchanged from last week. On the one hand, we wouldn’t think rescheduling cannabis would have much impact on psychedelics, but we also wouldn’t have thought valuations would actually be down. Could this represent sector rotation into cannabis now that the road ahead is a bit clearer?
Interestingly, the psychedelics sector had lower market-to-book ratios across all quartiles on 5/1/24 compared to 4/19/24. On an EV/revenue basis, the five companies with 2024 revenue estimates had a median EV/ 2024 revenue of 4.45x, unchanged from last week. On the one hand, we wouldn’t think rescheduling cannabis would have much impact on psychedelics, but we also wouldn’t have thought valuations would actually be down. Could this represent sector rotation into cannabis now that the road ahead is a bit clearer?
*Marijuana remains illegal under federal law. The Federal Government does not recognize marijuana to have any medicinal values. Marijuana cultivation, possession, consumption, sales, and distribution are illegal under federal laws and also certain state laws. Please note that there are differences in marijuana laws from one state, county, or city to another.
Copyright Viridian Capital Advisors © 2022